Payment overview · 2025
General Payments
$8,623.03
129 reported records · 25 companies
Healthcare provider profile · identity verified
Lance N Washington, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KOKOMO, IN · NPI 1356312128
Verified facts
What the public records show
CMS Open Payments records show Lance N Washington, MD received $8,623.03 in general payments during 2025 across 129 reported records.
Phathom Pharmaceuticals, Inc. accounted for 79.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti, Trintellix, Voquezna, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 530 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Voquezna by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6,813.67 | 79.0% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $289.02 | 3.4% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $244.33 | 2.8% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.08 | 2.2% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $187.64 | 2.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.59 | 1.8% | 13 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $108.38 | 1.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.70 | 1.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.57 | 0.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.22 | 0.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.56 | 0.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.17 | 0.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.39 | 0.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $37.29 | 0.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.82 | 0.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.56 | 0.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.42 | 0.4% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.48 | 0.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.91 | 0.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.41 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.64 | 0.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.83 | 0.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.23 | 0.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $14.64 | 0.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.48 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,440.00 | 5 |
| Food and Beverage | $2,032.53 | 121 |
| Travel and Lodging | $150.50 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6,813.67 | 14 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $211.01 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $194.15 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $194.15 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $190.08 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $175.65 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $175.65 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $102.78 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.94 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.94 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.65 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $63.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.59 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.18 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.71 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.53 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $6.15 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 143 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
530 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
143 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
353 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 983 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 599 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 544 | 105 |
| Jardiance | Empagliflozin | 530 | 77 |
| Gabapentin | Gabapentin | 387 | 78 |
| Losartan Potassium | Losartan Potassium | 356 | 82 |
| Eliquis | Apixaban | 353 | 38 |
| Omeprazole | Omeprazole | 346 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 345 | 83 |
| Furosemide | Furosemide | 339 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 58 |
| Lisinopril | Lisinopril | 297 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 292 | 77 |
| Trazodone Hcl | Trazodone Hcl | 290 | 43 |
| Sertraline Hcl | Sertraline Hcl | 284 | 33 |
| Prednisone | Prednisone | 282 | 167 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 59 |
| Potassium Chloride | Potassium Chloride | 247 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 50 |
| Carvedilol | Carvedilol | 192 | 48 |
| Ozempic | Semaglutide | 189 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 35 |
| Buspirone Hcl | Buspirone Hcl | 168 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 37 |
| Metformin Hcl | Metformin Hcl | 162 | 44 |
| Montelukast Sodium | Montelukast Sodium | 146 | 41 |
| Mounjaro | Tirzepatide | 143 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 34 |
| Meloxicam | Meloxicam | 139 | 42 |
| Tramadol Hcl | Tramadol Hcl | 138 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 32 |
| Allopurinol | Allopurinol | 128 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 20 |
| Donepezil Hcl | Donepezil Hcl | 115 | 19 |
| Farxiga | Dapagliflozin Propanediol | 112 | 22 |
| Alendronate Sodium | Alendronate Sodium | 106 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 21 |
| Famotidine | Famotidine | 98 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 24 |
| Simvastatin | Simvastatin | 98 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 20 |
| Pregabalin | Pregabalin | 88 | 29 |
| Trulicity | Dulaglutide | 87 | 19 |
| Risperidone | Risperidone | 85 | 11 |
| Topiramate | Topiramate | 84 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 61 |
| Torsemide | Torsemide | 80 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 21 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Memantine Hcl | Memantine Hcl | 72 | 14 |
| Azithromycin | Azithromycin | 71 | 60 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 24 |
| Nifedipine Er | Nifedipine | 70 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 21 |
| Primidone | Primidone | 69 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 13 |
| Spironolactone | Spironolactone | 66 | 21 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Mirtazapine | Mirtazapine | 63 | 13 |
| Admelog | Insulin Lispro | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 12 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 59 | 12 |
| Finasteride | Finasteride | 59 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Digoxin | Digoxin | 53 | suppressed |
| Baclofen | Baclofen | 52 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 24 |
| Cephalexin | Cephalexin | 51 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Olanzapine | Olanzapine | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 30 |
| Klor-Con M20 | Potassium Chloride | 40 | 15 |
| Glipizide | Glipizide | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Methylprednisolone | Methylprednisolone | 32 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Levofloxacin | Levofloxacin | 26 | 20 |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Nystatin | Nystatin | 25 | 15 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 11 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | 13 |
| Clonidine | Clonidine | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Levobunolol Hcl | Levobunolol Hcl | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Voquezna | Vonoprazan Fumarate | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,623.03 · 129 records | Phathom Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, INGREZZA, KISUNLA, Kerendia, Korlym, MONOFERRIC, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error